Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sciclone Pharmaceuticals Inc Issues FY 2013 Guidance; Revenue Guidance Below Analysts' Estimates


Monday, 7 Jan 2013 06:00am EST 

Sciclone Pharmaceuticals Inc announced that for fiscal 2013, it expects sales revenue of $150 million - $155 million and expects non-GAAP EPS of $0.66 - $0.72 per share. SciClone's non-GAAP EPS excludes employee stock-based compensation from GAAP EPS. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $157 million and EPS of $0.69 for fiscal 2013. 

Company Quote

8.85
-0.22 -2.43%
19 Dec 2014